Bristol Myers Squibb (BMY) Q4 FY24 earnings call

Bristol-Myers Squibb closed FY24 with strong growth in its diversified portfolio, driven by key assets like Cobenfy, Camzyos, and Opdualag. The company is actively reshaping its cost structure through an expanded productivity initiative while accelerating its late-stage pipeline, aiming for top-tier sustainable growth by the end of the decade. Despite near-term generic impacts and Medicare Part D pressures, management is confident in its strategic investments and operational excellence to deliver long-term value.